

REMARKS

Claims 2,3,6,8-11,13,16,17 and 19 are pending in the application; Claims 2,3,6,8-11,13,16,17 and 19 stand rejected. By this amendment, Claims 8, 16, 17 and 19 are further amended, and new Claims 20-25 are added. These amendments and new claims add no new matter to the application.

Claims 2,3,6,8-11,13,16,17 and 19 stand rejected under 35 USC 112 as allegedly containing subject matter not described in the specification in a way that reasonably conveys to one skilled in the art that the inventor had possession of the claimed invention. In particular, the Examiner has alleged that there is insufficient descriptive support for the generic limitation “an amyloid disease”. Applicant respectfully traverses these rejections. However in an effort to arrive at a mutually agreeable and earliest possible definition of allowable subject matter, Applicant has amended the current independent claims to recite two amyloid diseases only, both of which are abundantly discussed and supported in the specification, namely Alzheimer’s disease and Type II diabetes. According, amended Claims 8, 16, 17 and 19, and their respective dependent claims, are now believed to be in condition for allowance, and reconsideration is requested.

In addition, four new independent claims are presented and their entry and favorable examination is requested. It is believed that no new searching or examination is required for these claims as they are derived from the same subject matter as the existing independent claims. In particular, Claims 20-21 are composition alternates for claims 17 and 19. Claims 20-21 differ from claims 17 and 19 in that they are not directed to any particular disease or condition. Claims 22-23 are directed to the same compositions as claims 17 and 19, but are directed to treatment of amyloid fibrils, rather than particular diseases, and support for such treatment of amyloid fibrils is believed to be amply supported in the specification.

New dependent claims 24-25 are based on original claim 15, now cancelled, but further reciting that the efficacy is to be measured *in vitro*, thus addressing the previous ground of rejection for claim 15. Entry and favorable examination of these claims is also requested.

Applicant believes it has responded fully to all of the concerns expressed by the Examiner in the Office Action, and respectfully requests that new Claims be entered and examined, and that early favorable action be taken on all claims pending in the application. Applicant respectfully requests reexamination of all rejected claims and early favorable action on them as well. If the Examiner has any further concerns, Applicant requests an immediate call to Patrick Dwyer at (206) 550-4049.

Respectfully submitted,



PATRICK MICHAEL DWYER
Reg. No. 32,411

P07C13-OA3.RSP

PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109